|
시장보고서
상품코드
1565600
세계의 인공 망막 임플란트 시장 : 제품별, 용도별, 최종사용자별, 지역별 예측(-2032년)Global Artificial Retina Implant Market Research Report Information by Product, by Application, and by End User and by Region - Forecast till 2032 |
||||||
세계 인공 망막 임플란트 시장 규모는 2025년 15억 1,000만 달러, 2026년 19억 2,000만 달러에서 예측 기간 동안 21.22%의 CAGR로 2032년 70억 4,000만 달러 규모로 성장할 것으로 예상됩니다.
망막색소변성증과 노인성 황반변성(AMD)의 유병률 증가, 인공 망막 임플란트를 제공하는 스타트업의 증가가 세계 시장 확대의 주요 원인으로 꼽히고 있습니다.
지역별 전망
북미의 2025년 시장 점유율은 50.12% 이상입니다. 노화성 황반변성(AMD)의 유병률 증가와 FDA 승인을 받은 임플란트 제품이 출시되면서 북미 인공 망막 임플란트 시장이 가장 큰 점유율을 차지할 것으로 예상됩니다.
유럽 시장은 2025년부터 2026년까지 크게 확대될 것으로 예상됩니다. 이는 주로 고객의 수요를 충족시키기 위해 진입 기업들이 전략적 제휴를 자주 맺기 때문입니다.
아시아태평양의 인공 망막 임플란트 시장은 예측 기간 동안 가장 빠른 속도로 성장할 것으로 예상됩니다. 이는 이 지역의 노인 인구가 증가하고 있기 때문이며, 이는 산업 성장에 큰 기여를 할 것으로 예상됩니다. Asia-Pacific Report on Population Ageing 2022에 따르면, 2022년에는 아시아 태평양 지역의 60세 이상 인구가 6억 7,000만 명 이상이 될 것으로 추산됩니다. 아시아태평양에서는 2050년까지 인구가 3배 증가한 약 13억 명에 이를 것으로 예측됩니다.
세계 인공 망막 임플란트 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 성장 촉진요인
- 노인황반변성(AMD)과 망막색소변성증 발생률 증가
- 성장 억제요인
- 인공 망막 임플란트 수술에 따른 고액의 비용
- 기회
- 인공 망막 임플란트에 대한 자금과 투자 증가
제5장 시장 요인 분석
- Porter's Five Forces 분석
- 시력 상실을 치료하기 위한 뇌 임플란트를 개발하는 주요 기업
제6장 세계의 인공 망막 임플란트 시장 : 제품 유형별
- 개요
- 망막상 임플란트
- 망막하 임플란트
- 맥락막상 임플란트
제7장 세계의 인공 망막 임플란트 시장 : 용도별
- 개요
- 노인황반변성(AMD)
- 망막색소변성증
제8장 세계의 인공 망막 임플란트 시장 : 지역별
- 개요
제9장 경쟁 상황
- 경쟁 대시보드
- 공개 기업 주식 개요
- 비교 분석 : 주요 기업 재무 동향
- 주요 전개·성장 전략
제10장 기업 개요
- VIVANI MEDICAL INC.
- IBIONICS
- NANOVISION BIOSCIENCES
- SENSOR-TECH LAB
- LABTICIAN OPHTHALMICS, INC
- OPTOBIONICS
- LAMBDAVISION, INC.
- BIONIC VISION TECHNOLOGIES
- PIXIUM VISION
- AXORUS
- DATA CITATIONS
Global Artificial Retina Implant Market Research Report Information by Product (Enzymes, Pharma Products, Bulk Chemicals, and Others), by Application (Bioengineering, Genomics, Vaccine Development, Drug Discovery, Fisheries, Aquaculture, Biofuels, Water Treatment Services, and Others), and by End User (Hospitals, Pharmaceutical Companies, Biotechnology Companies, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032
Market Synopsis
The market for artificial retinal implants was estimated to be worth USD 1.51 billion in 2025. The Artificial Retina Implant market is expected to expand at a compound annual growth rate (CAGR) of 21.22% between 2026 and 2032, from USD 1.92 billion in 2026 to USD 7.04 billion.
The rising prevalence of retinitis pigmentosa and age-related macular degeneration (AMD), as well as the rise in the number of startups offering artificial retina implants, are the main reasons propelling the expansion of the global market.
In September 2021, Bionic Vision Technologies, a well-known brand in artificial retina technology, announced a significant collaboration with Cirtec Medical, a top medical technology business with its headquarters located in the US. The collaborative effort will facilitate the design process and allow for cooperative production of the next generation of bionic eyes. With the resources and expertise base of Cirtec Medical at its disposal, Bionic Vision Technologies hopes to advance its cutting-edge bionic eye technology and provide improved vision solutions for those with visual impairments.
Insights on Market Segments
The Artificial Retina Market is divided into three segments based on product type: suprachoroidal implants, subretinal implants, and epiretinal implants.
The artificial retina market has been divided into two segments based on application: retinitis pigmentosa and age-related macular degeneration (AMD).
Regional Perspectives
The market is divided into four regions by the study: North America, Europe, Asia-Pacific, and the Rest of the World. With a market share of more than 50.12% in 2025, the artificial retina implant market in North America held the biggest share due to the rising prevalence of age-related macular degeneration (AMD) and the availability of FDA-approved implant products. For example, Argus II is a product that the FDA has approved and is accessible in the United States.
The artificial retina implant market in Europe is expected to increase significantly between 2025 and 2026, primarily due to the frequent strategic alliances formed by industry participants to meet customer demand. For example, Pixium Vision (France) revealed in July 2022 that the first patient in the Netherlands had a successful implantation in the Prima System European pivotal trial PRIMAvera. Since then, Pixium Vision has created more clinical locations and implanted patients in the UK and Germany.
The Asia-Pacific artificial retina implant market is expected to develop at the quickest rate during the forecast period due to the region's growing geriatric population, which is expected to significantly contribute to the industry's growth. For example, the Asia-Pacific Report on Population Ageing 2022 estimates that 670 million or more persons in Asia-Pacific were 60 years of age or older in 2022. In the Asia-Pacific region, the population is predicted to treble to almost 1.3 billion by 2050.
Key Players
Bionic Vision Technologies (US), PIXIUM VISION (France), Optobionics (US), Labtician Ophthalmics, Inc. (Canada), Vivani Medical Inc. (US), iBIONICS (Canada), LambdaVision, Inc. (US), AXORUS (France), Sensor-Tech Lab (Russia), and Nanovision (US) are some of the prominent companies in the artificial retina implant market.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE AND ASSUMPTIONS
- 2.5 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
- 3.1 OVERVIEW
- 3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
- 3.3 PURCHASED DATABASE:
- 3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
- 3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
- 3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TECHNIQUE
- 3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
4 MARKET DYNAMICS
- 4.1 INTRODUCTION
- 4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF AGE-RELATED MACULAR DEGENERATION (AMD) AND RETINITIS PIGMENTOSA
- 4.2.2 GROWING NUMBER OF STARTUPS ASSOCIATED WITH ARTIFICIAL RETINA IMPLANT
- 4.3 RESTRAINTS
- 4.3.1 HIGH COST ASSOCIATED WITH ARTIFICIAL RETINA IMPLANT PROCEDURES
- 4.4 OPPORTUNITY
- 4.4.1 INCREASING FUNDING & INVESTMENT FOR ARTIFICIAL RETINA IMPLANT
5 MARKET FACTOR ANALYSIS
- 5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
- 5.2 KEY PLAYERS DEVELOPING BRAIN IMPLANTS TO TREAT VISION LOSS
6 GLOBAL ARTIFICIAL RETINA IMPLANT MARKET, BY PRODUCT TYPE
- 6.1 OVERVIEW
- 6.2. EPIRETINAL IMPLANTS
- 6.3. SUBRETINAL IMPLANTS
- 6.4. SUPRACHOROIDAL IMPLANTS
7 GLOBAL ARTIFICIAL RETINA IMPLANT MARKET, BY APPLICATION
- 7.1 OVERVIEW
- 7.2. AGE-RELATED MACULAR DEGENERATION (AMD)
- 7.3. RETINITIS PIGMENTOSA
8 GLOBAL ARTIFICIAL RETINA IMPLANT MARKET, BY REGION
- 8.1 OVERVIEW
9 COMPETITIVE LANDSCAPE
- 9.1 INTRODUCTION
- 9.2 COMPETITOR DASHBOARD
- 9.3 PUBLIC PLAYERS STOCK SUMMARY
- 9.4 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
- 9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 9.5.1 PARTNERSHIP
- 9.5.2 EXPANSION
- 9.5.3 MERGER
10 COMPANY PROFILES
- 10.1 VIVANI MEDICAL INC.
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 SWOT ANALYSIS
- 10.1.6 KEY STRATEGIES
- 10.2 IBIONICS
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 SWOT ANALYSIS
- 10.2.6 KEY STRATEGY
- 10.3 NANOVISION BIOSCIENCES
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 KEY STRATEGY
- 10.4 SENSOR-TECH LAB
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 PRODUCTS OFFERED
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 KEY STRATEGY
- 10.5 LABTICIAN OPHTHALMICS, INC
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 PRODUCTS OFFERED
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 SWOT ANALYSIS
- 10.5.6 KEY STRATEGIES
- 10.6 OPTOBIONICS
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 PRODUCTS OFFERED
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 KEY STRATEGIES
- 10.7 LAMBDAVISION, INC.
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 PRODUCTS OFFERED
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 SWOT ANALYSIS
- 10.7.6 KEY STRATEGIES
- 10.8 BIONIC VISION TECHNOLOGIES
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS/SERVICES OFFERED
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 KEY STRATEGIES
- 10.9 PIXIUM VISION
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS OFFERED
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 SWOT ANALYSIS
- 10.9.6 KEY STRATEGIES
- 10.10 AXORUS
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 FINANCIAL OVERVIEW
- 10.10.3 PRODUCTS OFFERED
- 10.10.4 KEY DEVELOPMENTS
- 10.10.5 KEY STRATEGIES
- 10.11 DATA CITATIONS
